Startup · $3.3m raised
Minneapolis, OS
Every investor coverage indicates participated in a round Sunshine Heart, Inc. raised.
| Investor | Rounds | Invested |
|---|---|---|
| Commercial Ready | Grant | - |
The transaction that ended Sunshine Heart, Inc.'s run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | Sep 2004 | - | GBS Ventures (14 Apr 2011), GBS Ventures (4 Feb 2011), GBS Ventures (16 May 2007) |
Companies Sunshine Heart, Inc. acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Sunshine Heart, Inc.. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Heart-failure device developer Sunshine Heart, dual listed on NASDAQ and the ASX, closed an underwritten public share offering netting roughly $14 million, with Canaccord Genuity as sole book-runner.
The ASX and NASDAQ-listed heart device maker names an investment banking executive to its board, citing his deal experience, as it readies a key US trial and a European study.
Sunshine Heart's CEO letter to investors reviews 2010: an A$13.2 million financing, C-Pulse trial growth at newly added hospitals, two senior R&D hires, and a website revamp.
ASX-listed heart device firm Sunshine Heart appoints US medtech executive Paul Buckman to its board, which now spans eight directors across Australia and the United States.
Sunshine Heart has locked in A$3.7 million from US institutional investors via Summer Street, with a larger rights issue of up to A$11 million still planned pending shareholder backing at an October meeting.
Sunshine Heart's C-Pulse heart-assist device has been implanted in a sixth trial patient, with Pennsylvania State University performing its first such procedure under US regulatory approval.
Sunshine Heart announces that two female patients at Louisville's Jewish Hospital are the first US women implanted with its C-Pulse heart assist system in an FDA-approved 20-patient feasibility trial.
Sunshine Heart's board will weigh ways to secure extra funding after starting its US heart device trial; finance chief Brian Bolton retires, with Rowena Hubble becoming company secretary.
Sunshine Heart says a Kentucky hospital is the first US site cleared by an ethics board to join its FDA-approved C-Pulse heart failure trial, with patient enrolment expected once contracts are signed.
Sunshine Heart won complete US regulator clearance to run its first American trial of the C-Pulse heart device, having satisfied conditions attached to September's conditional clearance; enrolment of trial participants was anticipated that year.
Sunshine Heart has eliminated its chief operating officer role, with Victor Windeyer departing as the company restructures its St Leonards operation; chief technical officer Dr William Peters resumes managing development.
Board change at Sunshine Heart: Nicholas Callinan takes the chairman role at the October 2008 annual meeting as Malcolm McComas steps down from it but stays a director; Callinan's venture capital career is profiled.
Sunshine Heart's medical director welcomes a US regulator panel's unanimous green light for Thoratec's Heartmate II, arguing his company's C-Pulse targets a larger, earlier-stage patient group.
Sunshine Heart's major shareholders CM Capital and GBS agreed a revised schedule for their $6 million share subscription, payable in two 2007 tranches with extra options, as the company seeks US trial approval.
Sunshine Heart's CEO showcased its C-Pulse cardiac support technology at a US bioventures conference; backer CM Capital attended, and the medtech firm readied US feasibility trials for its second-generation system.
A heart-device company has finished building an updated portable driver for its C-Pulse therapy system with a US manufacturing partner, completing preclinical work ahead of an American trial and regulator filing planned for 2007.
Also GBS Ventures·GBS Ventures
ASX-listed heart device maker Sunshine Heart has finished training clinicians at six US hospitals ahead of its C-Pulse feasibility trial, planned to start later in 2007.
Medical device firm Sunshine Heart closed a roughly A$3.3 million placement to institutional investors, funding its clinical trial and C-Pulse driver work; the release also cites an earlier A$2.2 million Commercial Ready grant.
Sunshine Heart appoints Victor Windeyer as chief operating officer to lead its Australian operations and C-Pulse clinical trials from Sydney; the company also cites a secured grant and ethics approvals at two Melbourne hospitals.
Also GBS Ventures
Medtech company Sunshine Heart has brought in Ruth Flynn as its first clinical affairs manager, to drive C-Pulse heart assist device trials across Australia and New Zealand from its Sydney head office.
ASX-listed medical device company Sunshine Heart appointed Melbourne heart transplant specialist Professor Don Esmore to its medical advisory board, which already includes academics from Penn State, Stanford and the Cleveland Clinic.
Surgeons in Auckland have placed the C-Pulse cardiac support device from Australian medtech Sunshine Heart into a patient for the first time, with further trial sites planned at Australian hospitals.